100-plus study welcomes 500th participantThe 100-plus study included its 500th centenarian last week. With this study, researchers want to unravel why some individuals suffer from symptoms of dementia at the age of 70, while others reach ages over 100 years without any signs of cognitive decline. With this milestone, Henne Holstege and her team at the Alzheimer Center Amsterdam have collected 50,000 years’ worth of knowledge.
Annemieke Rozemuller honored for her work within neurodegeneration researchOn March 27, 2025, Professor Annemieke Rozemuller bid farewell with her lecture, entitled "Neurodegeneration: Is it Solvable?". It was continued by a festive honoring, where Rozemuller was appointed Knight in the Order of Orange-Nassau for her extensive contributions to neuropathology and neurodegenerative disease research.
First patient completes new trial to test brain-cholesterol lowering Alzheimer’s medicationThe existing HIV medication Efavirenz may potentially also be effective for Alzheimer’s patients by lowering cholesterol in the brain. A clinical trial to test this began in fall 2024 at Amsterdam UMC, and now the first patient has completed treatment. Participants are still being recruited.
